NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE108979 Query DataSets for GSE108979
Status Public on Aug 23, 2018
Title Identification of the ER-beta cistrome in ER-beta expressing MDA-MB-231 cells [ChIP-seq]
Organism Homo sapiens
Experiment type Genome binding/occupancy profiling by high throughput sequencing
Summary We have utilized ChIPseq to identify the ER-beta cistrome in ER-beta expressing MDA-MB-231 triple negative breast cancer cells. ER-beta has been identified as a tumor suppressor in breast cancer and recent reports have demonstrated that ER-beta protein is detectable at moderate to high levels in approximately 30% of triple negative breast tumors. Increased expression of ER-beta in triple negative breast cancer has also been reported to be associated with improved recurrence-free survival. Treatment of ER-beta expressing triple negative breast cancer cells with estrogen, or the ER-beta selective agonist, LY500307, results in decreased cell proliferation, invasion and migration. To begin to identify the molecular mechanisms by which ER-beta elicits tumor suppressive effects in triple negative breast cancer, we performed ChIPseq studies and identified the genome-wide binding sites for ER-beta following exposure to 1nM estrogen or 10nM LY500307 for 3 hours. Over 28,000 and 10,000 unique ER-beta binding sites were identifed in response to these two ligands respectively. The top transcription factor motifs identified under both treatment conditions were estrogen response elements and AP1 response elements. The majority of ER-beta binding sites were found at enhancer regions located within introns or intergenic chromatin regions followed by gene promoters.
 
Overall design Examination of ER-beta binding sites in ER-beta expressing MDA-MB-231 cells. ER-beta immunoprecipitations were carried out using a Flag-specific antibody (M2). All treatment conditions were conducted in triplicate and data were normalized using input controls and compared to vehicle treated cells.
 
Contributor(s) Hawse JR, Carroll JS, Nelson AW
Citation(s) 30257941
Submission date Jan 09, 2018
Last update date Mar 27, 2019
Contact name Jason Carroll
E-mail(s) Jason.Carroll@cruk.cam.ac.uk
Phone +44 1223 769649
Organization name Cancer Research UK, Cambridge Institute
Street address Li Ka Shing Centre, Robinson Way
City Cambridge
ZIP/Postal code CB2 ORE
Country United Kingdom
 
Platforms (1)
GPL16791 Illumina HiSeq 2500 (Homo sapiens)
Samples (21)
GSM2918262 jc2831_MDA-MB-231-ERb_ERb_Full_24_hrs_Dox_3_hrs_ethanol
GSM2918263 jc2834_MDA-MB-231-ERb_ERb_Full_24_hrs_Dox_3_hrs_ethanol
GSM2918264 jc2836_MDA-MB-231-ERb_ERb_Full_24_hrs_Dox_3_hrs_ethanol
This SubSeries is part of SuperSeries:
GSE108981 Identification of the ERĪ² transcriptome in ER-beta expressing MDA-MB-231 cells
Relations
BioProject PRJNA429300
SRA SRP128615

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE108979_erb_estradiol-input_estradiol_peaks.narrowPeak.gz 660.9 Kb (ftp)(http) NARROWPEAK
GSE108979_erb_ethanol-input_ethanol_peaks.narrowPeak.gz 70.8 Kb (ftp)(http) NARROWPEAK
GSE108979_erb_ly500307-input_ly500307_peaks.narrowPeak.gz 247.8 Kb (ftp)(http) NARROWPEAK
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap